ID   L1210/DDP2
AC   CVCL_Y421
DR   Wikidata; Q54900961
RX   PubMed=3167012;
RX   PubMed=10200488;
CC   Selected for resistance to: ChEBI; CHEBI_27899; Cisplatin (CDDP).
CC   Transformant: ChEBI; CHEBI_34342; 3-methylcholanthrene (3-MC; 20-methylcholanthrene; 20-MC; MCA).
CC   Derived from site: In situ; Ascites; UBERON=UBERON_0007795.
CC   Cell type: T-cell; CL=CL_0000084.
CC   Breed/subspecies: DBA/2.
DI   NCIt; C21604; Mouse leukemia
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_0382 ! L1210
SX   Female
AG   8M
CA   Cancer cell line
DT   Created: 07-11-14; Last updated: 19-12-24; Version: 12
//
RX   PubMed=3167012; DOI=10.1021/bi00413a022;
RA   Eastman A., Schulte N.;
RT   "Enhanced DNA repair as a mechanism of resistance to
RT   cis-diamminedichloroplatinum(II).";
RL   Biochemistry 27:4730-4734(1988).
//
RX   PubMed=10200488; DOI=10.1038/sj.cdd.4400357;
RA   Segal-Bendirdjian E., Mannone L., Jacquemin-Sablon A.;
RT   "Alteration in p53 pathway and defect in apoptosis contribute
RT   independently to cisplatin-resistance.";
RL   Cell Death Differ. 5:390-400(1998).
//